Apontis Pharma AG Total Liabilities
Apontis Pharma AG total liabilities. Based on the latest financial reports, Apontis Pharma AG (APPH) has total liabilities worth €12.37 Million EUR (≈ $14.46 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Apontis Pharma AG liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Apontis Pharma AG (2018–2024)
Total liabilities of Apontis Pharma AG from 2018 to 2024. This chart illustrates how Apontis Pharma AG's total liabilities have evolved over time, based on quarterly financial data.
Apontis Pharma AG Competitors by Total Liabilities
The table below lists competitors of Apontis Pharma AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ufuk Yatirim Yonetim Ve Gayrimenkul AS
IS:UFUK
|
Turkey | TL370.56 Million |
|
Deleum Bhd
KLSE:5132
|
Malaysia | RM279.88 Million |
|
Reworld Media
PA:ALREW
|
France | €392.65 Million |
|
Cettire Ltd
AU:CTT
|
Australia | AU$88.51 Million |
|
Purit Co. Ltd.
KQ:445180
|
Korea | ₩18.83 Billion |
|
Melnick Even Desenvolvimento Imobiliário S.A
SA:MELK3
|
Brazil | R$1.59 Billion |
|
Gan Ltd
NASDAQ:GAN
|
USA | $91.63 Million |
|
Applied BioCode
TW:6598
|
Taiwan | NT$343.23 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Apontis Pharma AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Apontis Pharma AG (APPH) total assets.
Liquidity & Leverage Metrics
Apontis Pharma AG Total Liabilities Ratios Explained
Apontis Pharma AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apontis Pharma AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apontis Pharma AG (2018–2024)
The table below shows the annual total liabilities of Apontis Pharma AG from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €13.36 Million ≈ $15.62 Million |
-50.89% |
| 2023-12-31 | €27.20 Million ≈ $31.80 Million |
+48.72% |
| 2022-12-31 | €18.29 Million ≈ $21.38 Million |
+36.27% |
| 2021-12-31 | €13.42 Million ≈ $15.69 Million |
-48.84% |
| 2020-12-31 | €26.23 Million ≈ $30.67 Million |
+1.11% |
| 2019-12-31 | €25.94 Million ≈ $30.33 Million |
-6.70% |
| 2018-12-31 | €27.81 Million ≈ $32.51 Million |
-- |
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more